Biocrates Newsletter Issue #7

You can’t see this email? View it in your browser.
Deep Pheno Logo NL 2
Newsletter Issue #7
June 25, 2015
BileAcids Newsletter v2
The Renaissance of Bile Acids in Research and Diagnostics
 Hartmut Glossmann, M.D, Institute of Biochemical Pharmacology, Medical University Innsbruck; Innsbruck, Austria
Interest in bile acids has been growing since the discovery of their significance (especially secondary bile acids formed by the gut microbiota), hormone-like regulatory factors acting via nuclear-farnesoid-X receptor (FXR), and G-protein-coupled plasma-membrane bound receptors (TGR5), (Ridlon & Bajaj, 2015).
Simultaneous quantification of abundant and less abundant individual bile acids has become standard practice in the pharmaceutical industry. This includes the search for new drug targets for metabolic diseases (Thomas, Pellicciari, Pruzanski, Auwerx & Schoonjans, 2008), or proof-of-concept studies for novel drugs. The individual bile acid metabolome may provide insights into an individual’s diet (David et al., 2014), use of antibiotics, the gut microbiome, and many important health issues such as the prevention of gallstones, early discovery of factors that contribute to metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity- to mention a few.
By coupling high-resolution chromatography with mass spectrometry (Griffiths & Sjövall, 2010), it is now possible to exactly quantify individual bile acids in very small tissue samples (such as those obtained through biopsies), minute quantities of plasma, serum, urine, bile or feces of laboratory animals and humans. Although many excellent “home-grown” procedures are in the public domain, no commercial kit with a standardized protocol has been available so far. The Biocrates Bile Acids Kit might enable researchers to compare results across different laboratories.
Further Reading: Glossmann 2015: Bile Acids & Metabolic Syndrome; Bile Acids & Alzheimer's D.

Ridlon, J. M., & Bajaj, J. S. (2015). The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharmaceutica Sinica B, 1–7. doi:10.1016/j.apsb.2015.01.006
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008). Targeting bile-acid signalling for metabolic diseases. Nature Reviews. Drug Discovery, 7(august), 678–693. doi:10.1038/nrd261
David, L. a, Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E.,Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature, 505(7484), 559–63. doi:10.1038/nature12820
Griffiths, W. J., & Sjövall, J. (2010). Bile acids: analysis in biological fluids and tissues. Journal of Lipid Research, 51, 23–41. doi:10.1194/jlr.R001941-JLR200

PRODUCT NEWS

Analysis of Urine Using the AbsoluteIDQ® p180 Kit

Urine is a biofluid that provides extensive information. In contrast to blood it can be collected noninvasively. In addition to the p150 Kit of Biocrates, the p180 Kit is now optimized for the use of human urine, and permits the analysis of biogenic amines and amino acids among other substances. Download SOP for Urine
 

 

Sample Preparation Guidelines for Blood/ Tissue

We at Biocrates perform targeted analyses in a variety of biological matrices, such as plasma, serum, tissues, feces, urine, saliva, and cells of human and animal origin. The following guidelines must be followed in order to obtain results of high quality.
Download Sample Preparation Guidelines
 
 
NEWS & EVENTS

Metabolomics 2015
June 29-July 02, Burlingname, USA
Presentations on Biocrates products:
• Session - Cancer metabolism in human subjects; Presenter: Ismael Dale
• Session - Diabetes & Metabolic Syndrome Presenter; Weidong Zhang
• Session - Disease of the central nervous system; Presenter: John Newmann
Systems Biology of Human Disease
 July 06-08, Heidelberg, Germany

 
RESOURCES

Sample Preparation Guidelines
SOP AbsoluteIDQ p180 Kit and Urine
• Glossmann 2015: Bile acids and
   metabolic syndrome
• Glossmann 2015: Bile acids and Alzheimer's
Watch our videos on YouTube
• Join our LinkedIn Group

SAVE THE DATE: Oct, 22, 2015: Workshop Helmholtz Center Munich with Jules Griffin (more infos will follow soon)

 
 

Anton Pre analytical small

Anton et al., PLoS ONE 2015, 10 (3)

NEW PUBLICATION
Sample Preparation
SOPs for the pre-analytical phase and markers to distinguish between ‘good’ and ‘bad’ quality samples are urgently needed. Anton et al. studied the concentration changes of metabolites in serum samples using the Biocrates Kit. 
PloS ONE Free Full Text
 
 

Geurts Adipose small 2

Geurts et al., Nature Communications, 2015

NEW PUBLICATION
Obesity & Gut Microbiota
The  findings uncover the role of adipose tissue NAPE-PLD on whole-body metabolism and provide support for targeting NAPE-PLD-derived bioactive lipids to treat obesity and related metabolic disorders. Biocrates Services successfully contributed to the published results.
Nature Communications Free Full Text
 
About BIOCRATES
Biocrates Life Sciences AG, internationally renowned developer of targeted metabolic phenotyping solutions, supports the discovery and validation of biomarkers for complex multifactorial diseases in pre-clinical and clinical research.
Contact
BIOCRATES Life Sciences AG
Eduard-Bodem-Gasse 8, 6020 Innsbruck
+43 512 579823
+43 512 579823 329
marketing@biocrates.com
If you no longer wish to receive the BIOCRATES Life Sciences AG email newsletter, please click here to unsubscribe.
This email was sent by: BIOCRATES Life Sciences AG, Eduard-Bodem-Gasse 8, 6020 Innsbruck marketing@biocrates.com
Phone +43.512.579 823, Fax +43.512.579 823–329, FN 220414 p LG Innsbruck, UID No.: ATU 56725128
Powered by AcyMailing